Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon 14662, Korea.
Department of Obstetrics and Gynecology, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul 02841, Korea.
Int J Mol Sci. 2021 Dec 25;23(1):216. doi: 10.3390/ijms23010216.
Precision oncology involves an innovative personalized treatment strategy for each cancer patient that provides strategies and options for cancer treatment. Currently, personalized cancer medicine is primarily based on molecular matching. Next-generation sequencing and related technologies, such as single-cell whole-transcriptome sequencing, enable the accurate elucidation of the genetic landscape in individual cancer patients and consequently provide clinical benefits. Furthermore, advances in cancer organoid models that represent genetic variations and mutations in individual cancer patients have direct and important clinical implications in precision oncology. This review aimed to discuss recent advances, clinical potential, and limitations of genomic profiling and the use of organoids in breast and ovarian cancer. We also discuss the integration of genomic profiling and organoid models for applications in cancer precision medicine.
精准肿瘤学涉及为每个癌症患者制定创新的个性化治疗策略，为癌症治疗提供策略和选择。目前，个性化癌症药物主要基于分子匹配。下一代测序和相关技术，如单细胞全转录组测序，能够准确阐明个体癌症患者的遗传特征，并为临床带来益处。此外，代表个体癌症患者遗传变异和突变的癌症类器官模型的进步，在精准肿瘤学中具有直接而重要的临床意义。本综述旨在讨论基因组分析和类器官在乳腺癌和卵巢癌中的应用的最新进展、临床潜力和局限性。我们还讨论了基因组分析和类器官模型的整合在癌症精准医学中的应用。
